Business

FDA reveals drugmakers that game the system

By Robert King
Published May 17, 2018 3:35pm ET
Add Washington Examiner on Google
FDA reveals drugmakers that game the system
President Trump signed into law the FDA Reauthorization Act of 2017 on Friday. It reauthorizes a program in which drug and device makers pay the FDA a fee for every new product application, and the agency uses that money to hire more people and speed up approvals. (AP Photo/Andrew Harnik, File) | Andrew Harnik

The Food and Drug Administration on Thursday unveiled drugmakers that are limiting access to generic competition by denying access to their products.

The agency released a list of 52 brand name drugs to which generic companies are trying to get access in order to make a cheaper version. However, the generic companies have told the FDA that it is difficult to get access to the samples.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

FDA Pharmaceutical Industry